Regorafenib 40 mg, 80 mg, 120 mg, 160 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 40 mg, 80 mg, 120 mg, 160 mg

Reference Brands: Stivarga (USA/EU)

Category: Oncology Cancer Care

Regorafenib is a Oncology Cancer Care product available as Tablets in strengths 40 mg, 80 mg, 120 mg, 160 mg. It corresponds to the reference brand Stivarga (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Regorafenib is an oral multi-kinase inhibitor used for the treatment of several advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. It works by targeting multiple protein kinases involved in tumor growth, angiogenesis, and the tumor microenvironment. By inhibiting vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), TIE2, and oncogenic receptor tyrosine kinases, regorafenib helps block the growth of new blood vessels that tumors require and disrupts signaling pathways that support cancer cell proliferation and survival. This dual action as a kinase inhibitor and anti-angiogenesis agent makes it effective in controlling disease progression in patients with cancers that are resistant to standard therapies. Regorafenib is marketed under the brand name Stivarga and was developed by Bayer. It is taken orally and is typically prescribed under specialist supervision due to the need for careful monitoring of side effects, including hypertension, hand-foot skin reactions, liver toxicity, and gastrointestinal symptoms. The medication provides a targeted therapeutic option for patients with advanced cancers, offering improved disease management and the potential to extend survival in carefully selected patients.